Site Search Oral cyclic peptide PCSK9 inhibitor innovative drug development
2008
Originated from
2015
Establish Sungening Medicinal Chemistry R&D Center in Shenzhen
2021
Founded in
2023
Establish the cyclic peptide R&D platform
2024
SG1001 Granted Commercialization License
2025
Establish Sungening Hong Kong Clinical & Business Center
2026
Establish Sungening Longgang Cyclic Peptide R&D Center
85%
Proportion of scientific research team

About Sungening  

Fairness, Truth, Continuous Learning, Self-breakthrough


Sungening Biological Co., Ltd. is a clinical need-driven innovative drug developer specializing in AI-enabled cyclic peptide therapeutics.

The company focuses on high-value therapeutic areas including anti-infection and metabolic diseases. Leveraging mRNA display technology, AI-driven cyclic peptide molecular simulation, and proprietary technologies for cyclic peptide druggability optimization.

The company has built a well-tiered pipeline of R&D candidates. Its lead candidate has completed dual IND filings in China and the U.S. and is advancing steadily into global clinical development. We are dedicated to delivering more precise and safer therapeutic solutions to patients worldwide.


More>>
Sungening AI+Innovative drug development platform for cyclic peptides
AI + Cyclic Peptides Target
We pioneer integrated cyclic peptides target R&D via AI prediction and experimental validation. Based on multi-omics data and self-developed AI models, we screen cyclic peptides-suitable targets from disease pathways, focusing on undruggable PPI, GPCR and IDPs. We conduct druggability evaluation, binding analysis and functional verification at cellular and animal levels. We have built a professional evaluation system for cyclic peptides targets, effectively lowering early R&D risks and boosting the success rate of cyclic peptides drug development.
mRNA Display
Based on Sungening Bio’s internationally leading mRNA display technology derived from the PURE system, we construct cyclic peptides libraries with a scale of up to 10¹³. Catering to the screening demands for specific targets (such as protein-protein interaction interfaces and proteins without active pockets), we deliver high-affinity cyclic peptides hit sequences within weeks. We support high-throughput screening of cyclic peptides hit molecules against undruggable targets, enabling the de novo discovery of cyclic peptides ligands for complex protein-protein interaction interfaces.
Sungening Cyclic Peptides
Conduct in-depth chemical modification and affinity enhancement of cyclic peptides hit molecules. Systematically introduce tens of thousands of druggable building blocks such as unnatural amino acids and heterocyclic structures into the hit scaffold to construct a cyclic peptides-building block conjugate library. Through high-throughput affinity screening, rapidly identify super binders with elevated affinity and improved druggability after unnatural modification.
Cyclic Peptides Molecular Dynamics
We leverage integrated physical models and AI for computation-driven drug design. We offer full computational support from target analysis, binding pocket recognition to virtual screening and molecular optimization. We generate novel cyclic peptides via deep learning, apply FEP and molecular dynamics to assess binding affinity, and conduct early ADMET prediction to lower wet-lab costs.
Comprehensive Evaluation of Cyclic Peptides Druggability
We break the druggability bottleneck of innovative drugs from lead compounds to clinical candidates via systematic in vitro ADMET screening, early toxicity assessment, pre-formulation and in vivo PK/PD studies. We advance druggability evaluation alongside efficacy optimization, and build structure-property databases to deliver full solutions for high-quality PCC development. Sungening has optimized multiple projects such as SG6001 and SG1001 with solid practical experience.
Cyclic Peptides Innovative Assets
We offer full-cycle localized commercialization services for cyclic peptide drug R&D assets throughout their entire lifecycle. We cover patent planning & risk assessment, value appraisal, clinical and market-based valuation reports, as well as partnership matchmaking and licensing including technology transfer, joint development and exclusive authorization. We also provide financing support and pipeline incubation to maximize commercial value and accelerate industrialization.
Management team
Yan Chen, MD, PhD
Yan Chen, MD, PhD
Co-Founder/CTO
Chenguang Yuan, PhD
Chenguang Yuan, PhD
Co-Founder/CSO
Fanglin Li, PhD
Fanglin Li, PhD
SeniorVP
Xinyue Shen, PhD
Xinyue Shen, PhD
Director of AI
Yiguo Zhou, PhD
Yiguo Zhou, PhD
Director of Medicinal Chemistry
Dongmei He, PhD
Dongmei He, PhD
Director of Project Management
Ge Zhu , PhD
Ge Zhu , PhD
Director of Pharmacology, Toxicology and Project Management
Mengyao Guo , PhD
Mengyao Guo , PhD
BD Director
Get to know our latest updates
More>>
For protecting human health, we focus on the R&D of new drugs to solve unmet clinical needs

Telephone: 0755-28967200

Email: info@sungening.com

Copyright © Sungening Biological Co., Ltd. 粤ICP备2026014977号
Mainly engaged inOral cyclic peptide, PCSK9 inhibitor, innovative drug development, Welcome to inquire！
Technical Support： 华企立方 disclaimer
| Contact
  • 微信
    微信